Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation
Why the study?
Does rivaroxaban prevent ischemic stroke and systemic embolism in Japanese patients with non-valvular atrial fibrillation in real-world practice?
Population
7,178 Japanese patients with non-valvular atrial fibrillation, 32.2% female, enrolled across 684 medical…
Design
Cohort
Follow-up
mean approximately 2.5 years
Authors
Discussion
Loading...
Member takes
Overview
Real-world rivaroxaban use in Japanese NVAF patients shows low event rates; leaves open need for randomized confirmation before practice change.
Structured PICO
Does rivaroxaban prevent ischemic stroke and systemic embolism in Japanese patients with non-valvular atrial fibrillation in real-world practice?
P
Population
7,178 Japanese patients with non-valvular atrial fibrillation, 32.2% female, enrolled across 684 medical institutes.
I
Intervention
Rivaroxaban
O
Outcome
Effectiveness (prevention of ischemic stroke and systemic embolism) and safetycomposite
The EXPAND study describes the baseline characteristics of a large, real-world Japanese cohort of non-valvular AF patients treated with rivaroxaban.
Cite This Study
Ikeda et al. (2016) studied this question.